|
New Rochelle, NY, March 19, 2024—Mary Ann Liebert, Inc., is pleased that Cory Brooks, PhD, has been appointed the new Editor-in-Chief of the bimonthly journal Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. Dr. Brooks is replacing Thomas Kieber-Emmons, PhD, as Editor-in-Chief.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy provides authoritative, peer-reviewed research on the development of new genetic testing technologies and the ethical, legal, social, and economic issues associated with genetic testing. It is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers.
“Dr. Cory Brooks is a highly qualified candidate for the role of Editor-in-Chief of Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. He possesses extensive experience in using structural biology to understand antibody-antigen interactions. His research into nanobodies and cancer immunotherapy places him at the forefront of new technologies in antibody design and protein engineering,” said Dr. Kieber-Emmons.
“I am honored to have been given the opportunity to serve as Editor-in-Chief for Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. Antibody therapeutics are in the midst of a golden age. New technologies and ideas are poised to make transformative changes to how antibodies are leveraged to improve the lives of patients. I am excited to continue the exceptional stewardship of the journal provided by Dr. Thomas Kieber-Emmons,” said Dr. Brooks.
Dr. Cory Brooks is a Professor in the Department of Chemistry and Biochemistry at California State University Fresno. He completed his PhD at the University of Victoria (Canada) and was a Canadian Institutes of Health Research (CIHR) post-doctoral fellow at the University of Alberta (Canada). The Brooks lab employs structural biology and protein science to understand the molecular nature of antibody-antigen interactions. His research has particular emphasis on nanobodies and antibody carbohydrate interactions. Dr. Brooks has co-authored more than 40 publications, and holds grants from the National Cancer Institute of the NIH, CSUBIOTECH, as well as private research contracts from antibody biotechnology companies.
Mary Ann Liebert, Inc., would like to thank Dr. Thomas Kieber-Emmons for his many years of dedication and service to the journal. |
